Genome-Based Therapeutics Targeted Drug Discovery and Development: Workshop Summary (2012) / Chapter Skim
Currently Skimming:
Appendix B: Speaker Biographical Sketches
Appendix B: Speaker Biographical Sketches
Pages 65-80
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 65... ...
The NCTT's programs span the spectrum of translational science from RNAi biology to small molecule probe discovery to drug development, including genome-wide RNAi, the NIH Chemical Genomics Center (NCGC) , the Therapeutics for Rare and Neglected Diseases (TRND)
|
From page 66... ...
She is director of the University of Washington Center for Genomics and Healthcare Equality, a National Human Genome Research Institute center of excellence in ethical, legal, and social implications research, and codirector of the Northwest-Alaska Pharmacogenomic Research Network. Walter Capone, M.B.A., is the chief operating officer of the Multiple Myeloma Research Foundation (MMRF)
|
From page 67... ...
Davies was responsible for global research and development strategy at Pfizer and led a number of key research and development transformations, integrations, and mergers. As a former PwC management consultant and IBM business consulting research and development leader, he led and delivered complex engagements in major mergers and acquisitions, extensive restructuring and downsizing, research and development productivity projects, personalized medicine and diagnostics strategies, portfolio and decision making strategies, outsourcing, clinical research organization and partnering strategies, operational strategies in discovery and clinical development, enterprise risk management, Asia and emerging market strategies, out- and in-licensing, and commercial assessments of pipeline assets.
|
From page 68... ...
Dzau's vision is that academic health centers must lead the transformation through innovation, translation, and globalization. To achieve this vision he has established the Duke Translational Medicine Institute, Duke Global Health Institute, Duke Initiative in Health Innovation, and Duke National Univer
|
From page 69... ...
He moved in 1991 to lead the Department of Medicine and Experimental Therapeutics at University College, Dublin, and then returned in 1994 to the United States to take up direction of the Center for Experimental Therapeutics and the General Clinical Research Center as the Robinette Professor of Cardiovascular Medicine at Penn. These structures were subsumed into ITMAT when it was founded in 2004, anticipating the funding of clinical and translational research centers 2 years later by the NIH.
|
From page 70... ...
He has also published on science policy in the lay and professional press and is an occasional sports commentator for Il Manifesto. He has been awarded honorary degrees from University College Dublin and the Universities of Edinburgh and Frankfurt.
|
From page 71... ...
While at Duke, Dr. Ginsburg has pioneered translational genomics, initiating programs in genome enabled biomarker discovery, longitudinal registries with linked molecular and clinical data, biomarker-informed clinical trials, and the development of novel practice models and implementation research for the integration of genomic tools in heath care systems.
|
From page 72... ...
as senior program director for cardiovascular diseases and was eventually appointed vice president of Molecular and Personalized Medicine, where he was responsible for developing pharmacogenomic strategies for therapeutics, as well as biomarkers for disease and their implementation in the drug development process. He has received a number of awards for his research accomplishments, including the Innovator in Medicine Award from Millennium in 2004 and the Basic Research Achievement Award in Cardiovascular Medicine from Duke University in 2005.
|
From page 73... ...
Hamburg has emphasized the critical role of innovation in meeting the nation's rapidly growing public health needs. She provided leadership for the implementation of three groundbreaking measures: the Family Smoking Prevention and Tobacco Control Act, a 2009 law that gives FDA the authority to regulate the manufacture, distribution, and marketing of tobacco products; the Food Safety Modernization Act of 2011, which changed the focus of food safety measures from responding to food-borne outbreaks of illness to preventing them; and a thorough review of the system for the evaluation and approval of medical devices.
|
From page 74... ...
Ho plays a leadership role in integrating translational research efforts with experimental medicine strategies to define mechanism of action, understand pharmacodynamic relationships, identify rational therapeutic combinations, and investigate predictive biomarker hypotheses. He has focused on integrating drug and diagnostic development strategies, including the coordination of strategic collaborations supporting predictive diagnostic test development.
|
From page 75... ...
Peter Mueller, Ph.D., joined Vertex in July 2003. As executive vice president, global research and development, and chief scientific officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, pharmaceutical development, quality assurance and control, and pharmaceutical operations as well as clinical and nonclinical development, regulatory, and medical affairs.
|
From page 76... ...
Nisenbaum has applied pharmaco genomics across the neuroscience drug development portfolio to help tailor Lilly drugs for the right patient, leading to improved individual patient outcomes. Michael A
|
From page 77... ...
In 2002 Dr. Penny joined the clinical pharmacogenomics group at Pfizer in Sandwich, UK, and moved to New London, Connecticut, in 2006 to take on the role of oncology molecular medicine lead until 2009, when she moved to Indianapolis to lead the pharmacogenomics work at Eli Lilly and Company.
|
From page 78... ...
For the last 3 years he has headed up molecular medicine (now PharmaTx Precision Medicine) , which has been integrating molecular studies across disease areas as well as developing diagnostics for critical programs in the Pfizer product pipeline.
|
From page 79... ...
In 2005, she received an honorary doctorate from Iona College for her work in community engagement; the first Patient Service Award from the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy in 2007; the Research! America Distinguished Organization Advocacy Award in 2009; and the Clinical Research Forum and Foundation's Annual Award for Leadership in Public Advocacy in 2011.
|
From page 80... ...
80 GENOME-BASED THERAPEUTICS was responsible for Monsanto's external genomics relationships and held roles of vice president in the health and wellness sector, marketing director in Searle Pharmaceutical, and director in the agriculture division strategy.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.